Cross-Linked HA Did Not Outperform Saline - Summary - MDSpire
Advertisement
Cross-Linked HA Did Not Outperform Saline
Two single-injection cross-linked hyaluronic acid formulations showed no statistically significant advantage over saline for pain or functional outcomes through 24 weeks.
To compare the efficacy of Hyruan ONE, hylan G-F 20, and saline in reducing pain and improving function in patients with symptomatic knee osteoarthritis.
Approach:
Study Design: A single-center, double-blind, randomized, placebo-controlled trial involving 276 patients with symptomatic knee osteoarthritis.
Intervention: Patients received a single intra-articular injection of either Hyruan ONE, hylan G-F 20, or saline.
Outcome Measures: Primary outcomes included pain at rest and during motion measured on a 100-mm visual analog scale, with secondary outcomes including various functional and quality of life assessments.
Statistical Analysis: Linear mixed-effects models were used to analyze repeated measurements, accounting for treatment group, time, and demographic covariates.
Key Findings:
No statistically significant differences in pain or functional outcomes between Hyruan ONE, hylan G-F 20, and saline.
Pain scores decreased from baseline in all groups, but without significant between-group differences.
Most patient-reported outcomes improved from baseline, but Timed Up and Go performance did not show significant improvement.
Rescue corticosteroid use was similar across groups, with no significant differences.
Interpretation:
The improvement in the saline group aligns with previous evidence of responses to intra-articular saline injections.
Limitations:
24-week follow-up period with completion rates of approximately 73% to 80%.
Approximately 90% of participants had Kellgren-Lawrence grade II or III disease, excluding those with significant mechanical-axis deviation.
Adverse events were not systematically assessed.
Conclusion:
Intra-articular injections of ultra-high MW and HMW cross-linked HAs did not demonstrate superior efficacy in pain reduction or functional improvement compared with saline in patients with symptomatic knee OA.
Acidic gum beat sugar-free at cranking out nitric oxide from beetroot juice — exactly backward from what test-tube studies predicted. Also this week: a sleep gene that ignores amyloid, and jackfruit sap moonlighting as a bone-building drug delivery system.
With an aging population, spine disorders are becoming increasingly common. Age-related spinal degeneration is nearly universal, but not all patients experience symptoms—and not all degeneration progresses the same way.
